[go: up one dir, main page]

CL2009001250A1 - Sal del acido dihidroclorico y dibencensulfonico de 2-fluoro-n-metil-4-[7-(quinolin-6-ilmetil)imidazol[1,2-b][1,2,4]1,2,4]triazin-2-il]benzamida; compuestos intermediarios; procesos de preparacion; composicion farmaceutica; y uso para tratar cancer, aterosclerosis, fibrosis pulmonar, enfermedad renal, entre otras. - Google Patents

Sal del acido dihidroclorico y dibencensulfonico de 2-fluoro-n-metil-4-[7-(quinolin-6-ilmetil)imidazol[1,2-b][1,2,4]1,2,4]triazin-2-il]benzamida; compuestos intermediarios; procesos de preparacion; composicion farmaceutica; y uso para tratar cancer, aterosclerosis, fibrosis pulmonar, enfermedad renal, entre otras.

Info

Publication number
CL2009001250A1
CL2009001250A1 CL2009001250A CL2009001250A CL2009001250A1 CL 2009001250 A1 CL2009001250 A1 CL 2009001250A1 CL 2009001250 A CL2009001250 A CL 2009001250A CL 2009001250 A CL2009001250 A CL 2009001250A CL 2009001250 A1 CL2009001250 A1 CL 2009001250A1
Authority
CL
Chile
Prior art keywords
methyl
triazin
quinolin
imidazol
fluoro
Prior art date
Application number
CL2009001250A
Other languages
English (en)
Inventor
Pingli Liu
Jiacheng Zhou
Yongchun Pan
Lingkai Weng
Lei Qiao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41058602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009001250(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of CL2009001250A1 publication Critical patent/CL2009001250A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazol[1,2-b][1,2,4]triazin-2-il]benzamida; compuestos intermediarios; composición farmacéutica; proceso de preparación; útiles en el tratamiento del cáncer entre otras enfermedades.
CL2009001250A 2008-05-21 2009-05-20 Sal del acido dihidroclorico y dibencensulfonico de 2-fluoro-n-metil-4-[7-(quinolin-6-ilmetil)imidazol[1,2-b][1,2,4]1,2,4]triazin-2-il]benzamida; compuestos intermediarios; procesos de preparacion; composicion farmaceutica; y uso para tratar cancer, aterosclerosis, fibrosis pulmonar, enfermedad renal, entre otras. CL2009001250A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5499508P 2008-05-21 2008-05-21

Publications (1)

Publication Number Publication Date
CL2009001250A1 true CL2009001250A1 (es) 2010-02-05

Family

ID=41058602

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001250A CL2009001250A1 (es) 2008-05-21 2009-05-20 Sal del acido dihidroclorico y dibencensulfonico de 2-fluoro-n-metil-4-[7-(quinolin-6-ilmetil)imidazol[1,2-b][1,2,4]1,2,4]triazin-2-il]benzamida; compuestos intermediarios; procesos de preparacion; composicion farmaceutica; y uso para tratar cancer, aterosclerosis, fibrosis pulmonar, enfermedad renal, entre otras.

Country Status (30)

Country Link
US (7) US8420645B2 (es)
EP (2) EP3287449A3 (es)
JP (2) JP6022158B2 (es)
KR (1) KR101706784B1 (es)
CN (4) CN103936743B (es)
AR (3) AR071873A1 (es)
BR (1) BRPI0912882A2 (es)
CA (1) CA2724742C (es)
CL (1) CL2009001250A1 (es)
CO (1) CO6300934A2 (es)
CY (1) CY1119813T1 (es)
DK (1) DK2300455T3 (es)
EA (1) EA021364B1 (es)
EC (1) ECSP10010685A (es)
ES (1) ES2643363T3 (es)
HK (1) HK1251568A1 (es)
HR (1) HRP20171528T1 (es)
HU (1) HUE034716T2 (es)
IL (3) IL209229A (es)
LT (1) LT2300455T (es)
MA (1) MA32405B1 (es)
MX (3) MX393622B (es)
MY (3) MY155565A (es)
NZ (2) NZ589622A (es)
PL (1) PL2300455T3 (es)
PT (1) PT2300455T (es)
SI (1) SI2300455T1 (es)
TW (1) TWI472529B (es)
WO (1) WO2009143211A2 (es)
ZA (1) ZA201008212B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11542263B2 (en) 2018-04-18 2023-01-03 Neurocycle Therapeutics, Inc. Crystalline salts or co-crystals of 2′,6-difluoro-5′-[3-(1-hydroxy-1-methylethyl)-imidazo[1,2-b] [1,2,4]triazin-7-yl]biphenyl-2-carbonitrile with phosphoric acid as GABAA positive allosteric modulators

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5572388B2 (ja) 2006-11-22 2014-08-13 インサイト・コーポレイション キナーゼ阻害剤としてのイミダゾトリアジンおよびイミダゾピリミジン
JP6022158B2 (ja) * 2008-05-21 2016-11-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ ２−フルオロ−Ｎ−メチル−４−［７−（キノリン−６−イル−メチル）−イミダゾ［１，２−ｂ］［１，２，４］トリアジン−２−イル］ベンズアミドの塩及びそれを調製することに関する方法
ES2608329T3 (es) * 2010-02-03 2017-04-07 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazinas como inhibidores de c-Met
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
DE102013100596B4 (de) 2012-01-27 2023-09-07 Samsung Electronics Co. Ltd. Nichtflüchtiges Speichersystem mit Programmier- und Löschverfahren und Blockverwaltungsverfahren
US20150297604A1 (en) * 2012-04-03 2015-10-22 Novartis Ag Combination Products with Tyrosine Kinase Inhibitors and their Use
MX369518B (es) * 2012-08-16 2019-11-11 Novartis Ag Combinacion de inhibidor de p13k e inhibidor de c-met.
JP6449234B2 (ja) 2013-03-21 2019-01-09 ノバルティス アーゲー 併用療法
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
PL3172209T3 (pl) 2014-07-25 2021-06-14 Novartis Ag Formulacja tabletkowa 2-fluoro-n-metylo-4-[7-(chinolin-6-ylometylo)imidazo[1,2-b][1,2,4]triazyn-2-ylo]benzamidu
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
JP6526789B2 (ja) 2014-07-31 2019-06-05 ノバルティス アーゲー 組み合わせ療法
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
PE20171067A1 (es) 2014-10-14 2017-07-24 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas
HK1247089A1 (zh) 2015-03-10 2018-09-21 Aduro Biotech, Inc. 用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
MX2018007423A (es) 2015-12-17 2018-11-09 Novartis Ag Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
KR102482200B1 (ko) 2016-01-27 2022-12-27 우니페르지타에트 취리히 가려움증 치료를 위한 ｇａｂａａ 수용체 조절인자의 용도
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
CN106496000A (zh) * 2016-10-19 2017-03-15 蚌埠学院 一种3‑氟‑4‑溴‑苯乙酮的合成方法
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3642240A1 (en) 2017-06-22 2020-04-29 Novartis AG Antibody molecules to cd73 and uses thereof
PE20200717A1 (es) 2017-06-22 2020-07-21 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas
CN110526916B (zh) * 2018-05-23 2021-07-13 海创药业股份有限公司 氘代Capmatinib化合物及其用途
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021165818A1 (en) * 2020-02-17 2021-08-26 Novartis Ag Process and intermediates for the preparation of 2-fluoro-n-methyl-4-[7-quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2yl]benzamide
WO2021244551A1 (zh) * 2020-06-02 2021-12-09 正大天晴药业集团股份有限公司 c-Met激酶抑制剂和抗PD-L1抗体的联用药物组合物
CN111825678A (zh) * 2020-06-05 2020-10-27 连庆泉 一种卡马替尼的制备方法
WO2022007752A1 (zh) * 2020-07-06 2022-01-13 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
WO2022063869A2 (en) * 2020-09-24 2022-03-31 Merck Patent Gmbh Compounds for the treatment of viral infections
CN112480017A (zh) * 2020-11-13 2021-03-12 金仓(上海)医药生物科技有限公司 一种3-氨基-1,2,4-三嗪的制备方法
CN114853762A (zh) * 2021-02-03 2022-08-05 四川科伦药物研究院有限公司 一种咪唑并三嗪类化合物的固体形式及其制备方法和用途
AU2022336415A1 (en) 2021-09-01 2024-01-04 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
CN113896732B (zh) * 2021-10-13 2023-09-12 沈阳红旗制药有限公司 抗癌药物卡马替尼的制备方法及其应用
WO2023249994A1 (en) * 2022-06-22 2023-12-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN119775203B (zh) * 2024-11-29 2025-11-14 河北科技大学 一种卡马替尼中间体6-(3,3-二乙氧基丙基)喹啉的合成方法

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1411859A (en) 1920-12-08 1922-04-04 Marchand Robert Process for preparing hydrate of terpin
US2837520A (en) 1955-05-26 1958-06-03 Ind Chimica Profarmaco S R L Fluorescent materials on the basis of tetrazoindenes
US4220450A (en) 1978-04-05 1980-09-02 Syva Company Chemically induced fluorescence immunoassay
US4209621A (en) 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
US4405619A (en) 1981-09-02 1983-09-20 Diamond Shamrock Corporation Antiinflammatory substituted-1,2,4-triazolo[4,3-b]-1,2,4-triazines
DE3311753A1 (de) 1983-03-31 1984-10-04 Hoechst Ag, 6230 Frankfurt Substituierte 6-aryl-1,2,4-triazolo(4,3-b)pyridazine - ihre herstellung und verwendung -
DE3421029C2 (de) 1984-06-06 1986-04-24 Walter Steinhausen Mathis Verfahren und Vorrichtung zum trockenen Bedrucken eines Werkstückes unter Verwendung einer Heißprägefolie
JPS6337347A (ja) 1986-08-01 1988-02-18 Fuji Photo Film Co Ltd 直接ポジカラ−画像形成方法
JPS63199347A (ja) 1987-02-14 1988-08-17 Konica Corp 鮮鋭性の向上した高感度ハロゲン化銀写真感光材料
JPS63310891A (ja) 1987-06-12 1988-12-19 Yoshitomi Pharmaceut Ind Ltd 縮合ピリダジン化合物
US5236917A (en) 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
JPH0313934A (ja) 1989-06-12 1991-01-22 Konica Corp ハロゲン化銀写真感光材料
IL96432A0 (en) 1989-11-30 1991-08-16 Schering Ag Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
JP2664264B2 (ja) 1990-02-15 1997-10-15 富士写真フイルム株式会社 ハロゲン化銀写真乳剤及びこれを用いた写真感光材料
FR2662163A1 (fr) 1990-05-16 1991-11-22 Lipha Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant.
JPH04251243A (ja) 1991-01-09 1992-09-07 Konica Corp ハロゲン化銀写真感光材料
FR2671551B1 (fr) 1991-01-15 1993-03-12 Adir Nouveaux composes de structure aryl triazinique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05232618A (ja) 1992-02-21 1993-09-10 Konica Corp ハロゲン化銀写真感光材料
DE4309285A1 (de) 1993-03-23 1994-09-29 Boehringer Ingelheim Kg Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung
ES2137113B1 (es) 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
JP4251243B2 (ja) 1998-11-26 2009-04-08 株式会社日立メディコ 領域拡張装置
JP4025468B2 (ja) 1999-07-29 2007-12-19 三井化学株式会社 有機電界発光素子
UA70350C2 (en) 1999-11-10 2004-10-15 Ortho Mcneil Pharm Inc SUBSTITUTED 2-ARYL-3-(HETEROARYL)-IMIDAZO[1,2-a]PYSUBSTITUTED 2-ARYL-3-(HETEROARYL)-IMIDAZO[1,2-a]PYRIMIDINES, A METHOD FOR THE PREPARATION THEREOF (VRIMIDINES, A METHOD FOR THE PREPARATION THEREOF (VARIANTS) AND A PHARMACEUTICAL COMPOSITION BASED THARIANTS) AND A PHARMACEUTICAL COMPOSITION BASED THEREON EREON
BR0015420A (pt) 1999-11-12 2002-07-16 Neurogen Corp Composto, composição farmacêutica, métodos de tratamento de uma doença ou de um distúrbio associados com agonismo patogênio, para a localização de receptores gabaa, em uma amostra de tecido, de inibição da ligação de um composto de benzodiazepina em um receptor gabaa, e de alteração da atividade de transdução de sinal de receptores gabaa, agonismo inverso ou antagonismo do receptor gabaa, uso de um composto, e , composição faramcêutica embalada
NZ522783A (en) 2000-06-28 2004-07-30 Smithkline Beecham P Wet milling process for pharmaceuticals with agitator or chamber having nylon with internal lubricant
KR20030080087A (ko) 2001-03-09 2003-10-10 화이자 프로덕츠 인코포레이티드 항염증제로서의 트리아졸로피리딘
GB0107751D0 (en) 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
CA2448076A1 (en) 2001-05-24 2002-11-28 Masahiko Hayakawa 3-quinoline-2-(1h)-ylideneindolin-2-one derivatives
CN1281606C (zh) 2002-03-01 2006-10-25 安斯泰来制药有限公司 含氮杂环化合物
WO2003080621A1 (en) 2002-03-19 2003-10-02 Merck & Co., Inc. Process and intermediates to substituted imidazopyrimidines
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0210127D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
PA8580301A1 (es) * 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
MXPA05002123A (es) 2002-08-30 2005-06-06 Pfizer Prod Inc Nuevos procedimientos e intermedios para preparar triazolo-piridinas.
US6784297B2 (en) 2002-09-04 2004-08-31 Kopran Limited Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
KR101075812B1 (ko) 2002-12-18 2011-10-25 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서의 트리아졸로피리다진
RS53118B (sr) 2003-02-26 2014-06-30 Sugen Inc. Aminoheteroaril jedinjenja kao inhibitori protein kinaze
EP1640010A1 (en) 2003-07-01 2006-03-29 Astellas Pharma Inc. Agent inducing increase in bone mass
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
US7037909B2 (en) 2003-07-02 2006-05-02 Sugen, Inc. Tetracyclic compounds as c-Met inhibitors
JP2007516180A (ja) 2003-07-02 2007-06-21 スゲン，インコーポレイティド ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類
MXPA06000276A (es) 2003-07-02 2006-04-07 Sugen Inc Indolinona hidrazidas como inhibidores de c-met.
DE602004010680T2 (de) 2003-07-30 2009-01-02 Laboratorios S.A.L.V.A.T., S.A., Esplugues De Llobregat Substituierte imidazopyrimidine zur prävention und behandlung von krebs
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
JP2007506763A (ja) 2003-09-24 2007-03-22 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なイミダゾール組成物
PL2392565T3 (pl) 2003-09-26 2014-08-29 Exelixis Inc Modulatory c-Met i sposoby stosowania
US7144889B2 (en) 2003-10-16 2006-12-05 Hoffman-La Roche Inc. Triarylimidazoles
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
EA011402B1 (ru) 2004-01-23 2009-02-27 Эмджен Инк. Азотсодержащие гетероциклические производные и их фармацевтические применения
CA2553433A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
US7645756B2 (en) 2004-02-18 2010-01-12 Banyu Pharmaceutical Co. Ltd. Nitrogenous fused heteroaromatic ring derivative
EP2305682A1 (en) 2004-04-02 2011-04-06 OSI Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US20050277650A1 (en) 2004-04-20 2005-12-15 Sundaram Venkataraman Process for preparing aripirazole hydrate
EP1751136B1 (en) 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
WO2005121125A1 (en) 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
US7977345B2 (en) 2004-07-02 2011-07-12 Exelixis, Inc. c-MET modulators and method of use
AR053090A1 (es) * 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
US7361763B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
PT1786785E (pt) 2004-08-26 2010-05-21 Pfizer Compostos amino-heteroarilo enantiomericamente puros como inibidores da proteína quinase
US8030327B2 (en) 2004-11-08 2011-10-04 Mds K.K. Fused imidazole derivative
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
EP1841504B1 (en) 2005-01-13 2014-11-19 Bristol-Myers Squibb Company Substituted biaryl compounds as factor xia inhibitors
US20090156617A1 (en) 2005-05-12 2009-06-18 Northrup Alan B Tyrosine kinase inhibitors
EP1904501A2 (en) 2005-07-11 2008-04-02 Smithkline Beecham Corporation Chemical compounds
WO2007015866A2 (en) 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2007013673A1 (en) 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7728017B2 (en) 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
WO2007075567A1 (en) 2005-12-21 2007-07-05 Janssen Pharmaceutica, N.V. Triazolopyridazines as tyrosine kinase modulators
CA2634923C (en) 2005-12-23 2015-05-05 Ariad Pharmaceuticals, Inc. Acetylenic bicyclic heteroaryl compounds useful as kinase inhibitors
WO2007096764A2 (en) 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
JP2010500365A (ja) 2006-08-07 2010-01-07 インサイト・コーポレイション キナーゼ阻害剤としてのトリアゾロトリアジン
NZ575548A (en) * 2006-09-18 2011-09-30 Vertex Pharma Heterocyclic inhibitors of c-Met and uses thereof
EP2081937B1 (en) * 2006-10-23 2012-09-12 SGX Pharmaceuticals, Inc. Triazolopyridazine protein kinase modulators
MX2009004700A (es) 2006-11-06 2009-05-15 Supergen Inc Derivados de imidazo[1,2-b]piridazin y pirazolo[1,5-a] pirimidina y su uso como inhibidores de proteina cinasa.
JP5572388B2 (ja) 2006-11-22 2014-08-13 インサイト・コーポレイション キナーゼ阻害剤としてのイミダゾトリアジンおよびイミダゾピリミジン
AU2008254588B2 (en) 2007-05-21 2013-01-17 Sgx Pharmaceuticals, Inc. Heterocyclic kinase modulators
JP6022158B2 (ja) * 2008-05-21 2016-11-09 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ ２−フルオロ−Ｎ−メチル−４−［７−（キノリン−６−イル−メチル）−イミダゾ［１，２−ｂ］［１，２，４］トリアジン−２−イル］ベンズアミドの塩及びそれを調製することに関する方法
ES2608329T3 (es) 2010-02-03 2017-04-07 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazinas como inhibidores de c-Met

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11542263B2 (en) 2018-04-18 2023-01-03 Neurocycle Therapeutics, Inc. Crystalline salts or co-crystals of 2′,6-difluoro-5′-[3-(1-hydroxy-1-methylethyl)-imidazo[1,2-b] [1,2,4]triazin-7-yl]biphenyl-2-carbonitrile with phosphoric acid as GABAA positive allosteric modulators
US12134619B2 (en) 2018-04-18 2024-11-05 Neurocycle Therapeutics, Inc. Crystalline salts or co-crystals of 2′,6-difluoro-5′-[3-(1-hydroxy-1-methylethyl)-imidazo[1,2-b][1,2,4]triazin-7-yl]biphenyl-2-carbonitrile with p-toluenesulofonic acid as GABAA positive allosteric modulators

Also Published As

Publication number Publication date
ZA201008212B (en) 2014-04-30
KR101706784B1 (ko) 2017-02-14
CN113248510B (zh) 2025-01-17
MX393622B (es) 2025-03-24
CN108586463A (zh) 2018-09-28
JP6105653B2 (ja) 2017-03-29
US8420645B2 (en) 2013-04-16
HK1251568A1 (en) 2019-02-01
DK2300455T3 (en) 2017-10-30
ECSP10010685A (es) 2011-04-29
US12427154B2 (en) 2025-09-30
WO2009143211A3 (en) 2010-03-04
EA021364B1 (ru) 2015-06-30
US20150148348A1 (en) 2015-05-28
AU2009249154A1 (en) 2009-11-26
CA2724742C (en) 2016-07-19
AR111428A2 (es) 2019-07-10
HUE034716T2 (hu) 2018-02-28
US8901123B2 (en) 2014-12-02
IL229229A0 (en) 2013-12-31
US11452726B2 (en) 2022-09-27
EP3287449A3 (en) 2018-05-30
CN102083814B (zh) 2014-04-23
NZ602791A (en) 2014-04-30
CN103936743A (zh) 2014-07-23
PL2300455T3 (pl) 2018-02-28
AR071873A1 (es) 2010-07-21
US10799509B2 (en) 2020-10-13
IL229229A (en) 2017-05-29
US10245265B2 (en) 2019-04-02
JP2011520976A (ja) 2011-07-21
BRPI0912882A2 (pt) 2017-05-16
MA32405B1 (fr) 2011-06-01
TWI472529B (zh) 2015-02-11
LT2300455T (lt) 2017-11-10
SI2300455T1 (sl) 2017-12-29
US20210128568A1 (en) 2021-05-06
MY199552A (en) 2023-11-07
MX2019011954A (es) 2019-10-30
TW201008943A (en) 2010-03-01
US20090291956A1 (en) 2009-11-26
US20230098850A1 (en) 2023-03-30
IL209229A (en) 2015-11-30
IL209229A0 (en) 2011-01-31
AU2009249154B2 (en) 2014-12-11
JP6022158B2 (ja) 2016-11-09
MY187131A (en) 2021-09-02
AR123240A2 (es) 2022-11-09
CN103936743B (zh) 2018-04-24
MX368802B (es) 2019-10-17
EA201071337A1 (ru) 2011-06-30
EP2300455B1 (en) 2017-07-19
JP2015145378A (ja) 2015-08-13
ES2643363T3 (es) 2017-11-22
CO6300934A2 (es) 2011-07-21
CY1119813T1 (el) 2018-06-27
KR20110037962A (ko) 2011-04-13
CA2724742A1 (en) 2009-11-26
MX2010012718A (es) 2011-04-04
US20130289036A1 (en) 2013-10-31
HRP20171528T1 (hr) 2017-11-17
IL249651A0 (en) 2017-02-28
IL249651A (en) 2017-10-31
EP3287449A2 (en) 2018-02-28
NZ589622A (en) 2012-10-26
MY155565A (en) 2015-10-30
PT2300455T (pt) 2017-10-19
CN102083814A (zh) 2011-06-01
US20190167692A1 (en) 2019-06-06
EP2300455A2 (en) 2011-03-30
CN113248510A (zh) 2021-08-13
WO2009143211A2 (en) 2009-11-26
US20170258800A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
CL2009001250A1 (es) Sal del acido dihidroclorico y dibencensulfonico de 2-fluoro-n-metil-4-[7-(quinolin-6-ilmetil)imidazol[1,2-b][1,2,4]1,2,4]triazin-2-il]benzamida; compuestos intermediarios; procesos de preparacion; composicion farmaceutica; y uso para tratar cancer, aterosclerosis, fibrosis pulmonar, enfermedad renal, entre otras.
ME02322B (me) Kinazni inhibitor koji reguliše signalni put apoptoze
EA201171306A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-α]ПИРИДИНА, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКРЕТАЗЫ
BRPI0811534A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticametne aceitável do mesmo.
EA201291310A1 (ru) Композиция ингибитора jak для местного применения
BRPI0407430A (pt) Sal do ácido benzenossulfÈnico com clopidogrel, processos para preparação do mesmo, e para purificação de clopidogrel, uso de um sal, formulação farmacêutica, partìculas de substância ativa, uso de partìculas de substância ativa, e, processo para preparação de partìculas de substância ativa
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
EA201171286A1 (ru) Новая технология изготовления индометацина
EA201000552A1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
BR112013007123A2 (pt) processo de fabricação para derivados depirimidina
EA201100613A1 (ru) Конденсированные, спироциклические гетероароматические соединения для лечения бактериальных инфекций
EA201300556A1 (ru) Аминоспиртзамещенные производные 2,3-дигидроимидазо[1,2-с] хиназолина, пригодные для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
EA201500448A1 (ru) Гуанидиновое соединение
WO2009098715A3 (en) Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
EA201171284A1 (ru) Новая технология изготовления напроксена
CL2007003472A1 (es) Sal fumarato de (alfa s,beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol; proceso de preparacion; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamie
WO2014152278A3 (en) Coumarin derivatives and methods of use in treating hyperproliferative diseases
MX2018012165A (es) Metodos de tratamiento de canceres pediatricos.
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
ATE543492T1 (de) Behandlung von lungenkrebs
BRPI0911678B8 (pt) maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central
BRPI0720236A2 (pt) Composto ou sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar uma infecção bacteriana em um animal de sangue quente tal como o ser humano, e, composição farmacêutica
CL2007003160A1 (es) Compuestos derivados de piridina; procedimiento de preparacion; formulacion farmaceutica; y uso en el tratamiento de enfermedades tales como trombosis, fibrosis renal, isquemia, entre otras.
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
AR049916A1 (es) Usos anti-parasitarios de complejos de acido borinico